Ublituximab + TGR-1202 Demonstrates Activity and Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL. By admin / 06/20/2015
Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 MAB, in Combination with Ibrutinib Achieves 95% ORR in Patients with High-Risk Relapsed/Refractory CLL. By admin / 06/20/2015
Safety and Activity of the Chemotherapy-Free Triplet of Ublituximab, TGR-1202, and Ibrutinib is Safe and Highly Active in Relapsed B-Cell Malignancies. By admin / 06/20/2015
Clinical Activity and Safety Profile of TGR-1202, a Novel Once Daily PI3K-Delta Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile, Lacking Hepatotoxicity in Patients with CLL and B-Cell Lymphoma. By admin / 06/20/2015
Ublituximab + TGR-1202 Demonstrates Activity and Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL. By admin / 06/14/2015
Clinical Activity and Safety Profile of TGR-1202 a Novel Once Daily PI3K-Delta Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile, Lacking Hepatotoxicity, in Patients with CLL and B-Cell Lymphoma. By admin / 06/14/2015
Ubliuximab +TGR-1202 Demonstrates Activity and Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL. By admin / 06/02/2015
Safety and Activity of the Chemotherapy-free Triplet of Ublituximab, TGR-1202 and ibrutinib in Relapsed B-cell Malignancies. By admin / 06/02/2015
Clinical Activity and Safety Profile of TGR-1202, a Novel Once Daily Pi3k Delta Inhibitor, in Patients with CLL and B-Cell Lymphoma. By admin / 06/02/2015
IRAK4 inhibitors display synergistic activity when combined with BTK or PI3K inhibitors in B-cell lymphomas. By admin / 04/18/2015
